News

Filter

Teva pays $40 million upfront to market Alexza's Adasuve in USA

09-05-2013

The US subsidiary of Israeli generics giant Teva Pharmaceuticals Industries (NYSE: TEVA) has entered…

AdasuveAlexza PharmaceuticalLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

FDA sets PDUFA date for Alexza's resubmission for Adasuve

08-07-2012

Following two earlier rejections, the US Food and Drug Administration has now accepted Alexza Pharmaceuticals…

AdasuveAlexza PharmaceuticalFerrer InternacionalNeurologicalNorth AmericaPharmaceuticalRegulation

Alexza rockets on re-submission of Adasuve NDA

25-06-2012

USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) saw its shares soar 44.9% to close at $3.97 on Friday,…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

FDA again rejects Alexza's Adasuve, citing manufacturing deficiencies

07-05-2012

California, USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) revealed last week that it has received another…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

PDUFA goal date for Alexza’s Adasuve extended, as Public Citizen says drug should not be approved

25-01-2012

US drug firm Alexza Pharmaceuticals (Nasdaq: ALXA) says that the US Food and Drug Administration will…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

Jazz Pharma and Alexza/Valeant get FDA complete response letters, delaying JZP-6 and Staccato, respectively

12-10-2010

Two bits of negative news came out of the US Food and Drug Administration that will delay the approvals…

Alexza PharmaceuticalJazz PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationResearchValeant Pharmaceuticals

COMPANY SPOTLIGHT

Menarini

Back to top